Resources for Researchers

NIAID offers many resources to support your research, including reagents, model organisms, and tissue samples, to name just a few. Use the filters under Filter Search Results to narrow your search, or simply enter specific search terms in the search field.

108 Results

NIAID Clinical Trials Data Repository, AccessClinicalData@NIAID, is an NIAID cloud-based, secure data platform that enables sharing of and access to anonymized individual, patient level clinical data sets from NIAID sponsored clinical trials to harness the power of data to generate new knowledge to understand, treat, and prevent infectious diseases such as COVID-19.

The ACTG NL consists of Core Laboratory groups in immunology, pharmacology, virology and TB.

The specimen repositories are a collaboration between the ACTG and IMPAACT clinical trial networks to make the large body of specimens collected for HIV research available to investigators.

The specimens stored at the repositories were initially collected for specific studies that have concluded, and are now available to investigators conducting new research.

The aerobiology team develops aerosol animal models of disease caused by high-consequence pathogens. Using advanced inhalational technologies, this team provides high experimental reproducibility to ensure the best modeling possible. Aerosolization procedures are fine-tuned to achieve accurate and precise dosimetry.

The AIDS Imaging Research Section (AIRS) leverages preclinical and translational molecular imaging to study the pathogenesis of human immunodeficiency virus (HIV) infection using the simian/simian-human immunodeficiency virus (SIV/SHIV) nonhuman primate model.

Developing, characterizing, and refining animal models rely on sophisticated medical imaging equipment; aerosol capabilities; and virology, pathology, molecular biology, and immunology expertise.

The ARLG biorepositories were created to aid in the development and evaluation of novel diagnostic tests and laboratory techniques, study mechanisms of resistance, generate preliminary data for study concepts, and support/mentor early-stage investigators pursuing research in the field of antibacterial resistance.

Artificial intelligence (AI), in its many forms, is applied to infectious disease research at the IRF-Frederick. Primarily focused on medical imaging of preclinical models, state of the art methods are developed, applied to ongoing research and translated to human studies of disease.

The BEI Resources Repository is a central repository that supplies organisms and reagents to the broad community of microbiology and infectious diseases researchers. Materials are available through an online catalog.

The NIAID-funded Bioinformatics Resource Centers provide data-driven, production-level, sustainable computational platforms to enable sharing and access to data, portable computational tools, and standards that support interoperability for the infectious diseases research community. 

NIAID CEIRS provides the BEI Resources Repository with high-priority reagents from the CEIRS community. Reagents include plasmids, antibodies, proteins, and virus isolates. Reagents not available through BEI can be requested on this page. Non-BEI reagents may be available from CEIRS researchers upon request.

The CIBMTR database contains data on outcomes of hematopoietic (blood and bone marrow) cell transplant (HCT) procedures. The CIBMTR collaborates with government agencies, professional groups, international partners, and patient organizations via 15 active scientific/research working committees.

The Centers for Research on Structural Biology of Infectious Diseases (CRSTAL-ID) provide the research community with: 3-D protein structures and protein-ligand complexes; Sequence-verified clones and peptides; Services that deliver requested 3-D structure determination; and Molecular screening of proteins in complex with inhibitors, cofactors and substrate analogs

The ChemDB database contains information extracted from scientific literature on the structure and activity of compounds that have been tested against HIV, opportunistic pathogens and TB. This database is continually updated with information extracted from published literature, including the chemical structure and biological activity of compounds.

The Chemistry Center for Combating Antibiotic-Resistant Bacteria (CC4CARB) is a NIAID-led partnership with RTI International, which oversees the design, synthesis, and management of external investigator-submitted libraries of chemical compounds specifically targeting Gram-negative bacteria.

The Clinical Studies Support Team (CSST) develops and fosters overseas relationships through continuous support of research studies and clinical trials involving pathogens of high consequence. When deployed, the team provides in-person training and assistance with assays, equipment, and project management.

ClinRegs is an online database of country-specific clinical research regulatory information designed to assist in planning and implementing international clinical research.

CARD is a comprehensive web-application for integrated analysis and interactive visualization of RNA interference (RNAi) screening data.

The core services team provides cell culture, hematology, hemostasis, clinical chemistry, microbiology, and molecular virology support for infectious disease studies at the IRF-Frederick. The team has the ability to perform pre-screening assessment by having parallel setups of clinical analyzers in biosafety level 4 (BSL-4) and BSL-2.

The RSC Public Website, run by the DAIDS Regulatory Support Center (RSC) contractor, has been used in the DAIDS community for over 10 years and is a primary platform to communicate updates to templates, process changes, and other information needed by the RSC research community.

Repository of specimens collected as part of the DAIDS VAX004 Clinical Trial.

The STAT3base contains a listing of STAT3 mutations in human HIES identified in the Laboratory of Clinical Immunology and Microbiology as well as those published in the literature.

NIAID’s Diagnostics Development Services program offers reagents, platform testing, and planning and design support to accelerate product development of in vitro diagnostics (IVD) for infectious diseases, from research feasibility through clinical validation.

The drug screening team tests and characterizes novel compounds, drugs, and antibodies against numerous viruses in multiple cell lines under a variety of conditions. Compounds are evaluated in cell-based assays for inhibition of viral replication and reduction of virus yields, plaques, or cytopathic effect.

The Early Phase Clinical Trial Units (EPCTUs) support the design, development, implementation, and conduct of Phase 0 to Phase 2 clinical trials, including proof-of-concept studies in healthy, special, and disease-specific populations, carried out in an expeditious and efficient manner, aided by bioanalysis when necessary, against viral, bacterial, parasitic, and fungal pathogens and